Clinical trial
18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology
NCT00207298 · British Columbia Cancer Agency, Other · Completed
Key facts
| NCT number | NCT00207298 |
|---|---|
| Title | 18F-fluorodeoxyglucose (18F-FDG) Positron Emission Tomography in Oncology |
| Official title | Phase III Open Label Trial for Use of [18F]-Fluoro-Deoxy-Glucose (18F-FDG) in Positron Emission Tomography Imaging in Oncology |
| Lead sponsor | British Columbia Cancer Agency, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Brain Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Colorectal Neoplasms |
| Intervention type | Procedure |
| Interventions | Positron Emission Tomography |
| Enrollment | 39,242 |
| Start date | Jun 1, 2005 |
| Primary completion | Aug 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Sep 21, 2005 |
| Last update posted | Jan 10, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: